Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 39.78M | 35.58M | 20.76M | 31.10M | 45.78M | 33.20M |
Gross Profit | 33.92M | 35.58M | -96.95M | 23.52M | 42.88M | -44.27M |
EBITDA | -99.67M | -103.37M | -122.10M | -124.28M | -78.84M | -62.89M |
Net Income | -103.28M | -105.32M | -132.49M | -126.50M | -86.04M | -66.33M |
Balance Sheet | ||||||
Total Assets | 319.52M | 349.60M | 376.45M | 430.84M | 506.76M | 400.14M |
Cash, Cash Equivalents and Short-Term Investments | 215.09M | 244.90M | 253.68M | 337.12M | 309.28M | 371.69M |
Total Debt | 64.37M | 65.76M | 70.98M | 87.15M | 42.88M | 22.92M |
Total Liabilities | 124.38M | 133.62M | 130.34M | 141.61M | 117.16M | 119.35M |
Stockholders Equity | 195.14M | 215.99M | 246.11M | 289.23M | 389.61M | 280.79M |
Cash Flow | ||||||
Free Cash Flow | -80.50M | -65.34M | -108.55M | -111.44M | -88.24M | -67.90M |
Operating Cash Flow | -80.32M | -65.16M | -106.84M | -105.94M | -86.97M | -67.25M |
Investing Cash Flow | 31.25M | -51.27M | 158.35M | 58.42M | -189.34M | -190.50M |
Financing Cash Flow | 10.71M | 45.34M | 45.49M | 1.15M | 171.40M | 348.93M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $7.50B | 0.31 | -61.87% | 2.27% | 17.10% | 1.59% | |
46 Neutral | $90.66M | ― | -59.45% | ― | ― | 48.92% | |
43 Neutral | $105.09M | ― | -45.55% | ― | 98.56% | 37.97% | |
43 Neutral | $69.92M | ― | -62.34% | ― | ― | 86.65% | |
41 Neutral | $86.50M | ― | -62.04% | ― | ― | -61.95% | |
36 Underperform | $121.45M | ― | -49.72% | ― | ― | ― | |
33 Underperform | $238.67M | ― | -125.43% | ― | ― | 2.98% |
On June 18, 2025, C4 Therapeutics held its Annual Meeting of Stockholders, where key decisions were made regarding the company’s governance and operational strategies. Stockholders elected three Class II directors, approved executive compensation, ratified KPMG LLP as the independent auditor, and agreed to amend the company’s certificate of incorporation to double the authorized shares of common stock, reflecting strategic growth ambitions.
The most recent analyst rating on (CCCC) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.
On May 7, 2025, C4 Therapeutics announced updates from its Phase 1 clinical trial of cemsidomide, a small-molecule degrader for multiple myeloma (MM) and non-Hodgkin’s lymphomas (NHL). The trial’s dose escalation phase in MM is complete, with the 100 µg QD dose level showing a 50% overall response rate, including a complete response in one patient. The trial continues for NHL, with the maximum tolerated dose not yet reached. C4T plans to prioritize cemsidomide’s development and expects regulatory feedback by mid-2025 to support further clinical development in 2026. Financially, C4T reported a net loss of $26.3 million for Q1 2025, with cash reserves expected to fund operations into 2027.
On April 10, 2025, Bruce Downey announced his retirement from the Board of Directors of C4 Therapeutics and will not stand for reelection at the 2025 Annual Meeting of Stockholders. His departure is not due to any disagreements with the company’s strategy or operations, and he will step down from various committee roles following the meeting.